Randox unveils cytokine tests
June 22, 2020—Randox Laboratories has unveiled cytokine testing for COVID-19 risk stratification and treatment monitoring.
Webinars and Sponsored Roundtables — Register Now
Tuesday, October 20, 2026, 11 AM-12 PM ET
Hear experts review the biological and clinical significance of the HER2 expression continuum in breast tissue, providing a clearer understanding of how these variations might impact diagnosis, and discuss the emerging importance of documenting HER2-low and HER2-ultralow categories using a validated IHC assay.
Webinar presenters Keith Wharton, MD, PhD, Global Medical Affairs Leader–Pathology, Roche Diagnostics Solutions, and Hannah Y. Wen, MD, PhD, Director, Breast Pathology Fellowship, Associate Team Leader, Breast Pathology Team, Attending Pathologist, Memorial Sloan Kettering Cancer Center
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Roche.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Thursday, October 29, 2026, 1 PM-2 PM ET
Hear an expert discuss the evolving role of PD-L1 testing in HNSCC and ovarian cancer.
Webinar presenter Georgios Deftereos, MD, Professor of Pathology, Associate Director of the Clinical Cancer Genomics Laboratory, Director of Molecular Cytopathology, University of California, San Francisco
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Agilent.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Tuesday, November 3, 2026, 1 PM-2 PM ET
Hear an expert discuss the challenges of detecting NRG1 fusions and how RNA-based testing can support more comprehensive fusion identification in clinical practice.
Webinar presenter Benjamin Weinberg, MD, Associate Professor of Medicine and Attending Physician
specializing in gastrointestinal medical oncology
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Diaceutics.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Monday, November 16, 2026, 12:30 PM-2 PM ET
Hear experts discuss a multidisciplinary approach to oncopathology for HER2
assessments for solid tumors in the absence of a companion diagnostic.
Webinar presenters Funda Meric-Bernstam, MD, Chair, Department of Investigational Cancer Therapeutics Medical Director, Institute for Personalized Cancer Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas, and Emina E. Torlakovic, MD, PhD, College of Medicine, University of Saskatchewan, Canadian Biomarker Quality Assurance, Saskatoon, Saskatchewan, Canada, and Carol Cheung, MD, PhD, JD, FRCPC, Deputy Director, Canadian Biomarker Quality, Assurance—Programme canadien d’assurance de la qualité des biomarqueurs
CAP TODAY does not endorse any of the products or services named within. This program is being sponsored by Daiichi Sankyo, Inc. and AstraZeneca. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Subspecialties
Interactive Product Guides
Randox Laboratories
Randox ToRCH quality controls get CE mark
June 10, 2020—Randox Laboratories ToRCH quality controls for infectious disease testing in newborns have been granted the CE mark.
Randox unveils molecular controls for SARS-CoV-2
April 23, 2020—Randox Laboratories has developed Randox Qnostics SARS-CoV-2 whole pathogen quality controls designed for laboratories managing COVID-19 testing to help ensure the accuracy and reliability of molecular assays used in the testing of suspected coronavirus samples.
Randox STI assay gets CE mark
April 2020—Randox announced that its Randox STI assay has received the CE mark. The multiplex assay detects 10 STIs, including co-infections, from a single patient sample. It tests simultaneously for Chlamydia trachomatis, Neisseria gonorrhoeae, Trichomonas vaginalis, Mycoplasma genitalium, Treponema pallidum, HSV-1, HSV-2, Haemophilus ducreyi, Mycoplasma hominis, and Ureaplasma urealyticum.
Vivalytic test for detecting SARS-CoV-2
April 1, 2020—Randox Laboratories and Bosch Healthcare Solutionswill launch this month the Vivalytic Viral Respiratory Tract Infection Array, which can identify SARS-CoV-2 and differentiate it from nine other respiratory infections with similar symptoms, including influenza and all known coronaviruses.
Randox STI assay gets CE mark
March 6, 2020—Randox announced that its Randox STI assay has received the CE mark. The multiplex assay detects 10 STIs, including co-infections, from a single patient sample.
Randox introduces test for COVID-19
Feb. 19, 2020—Randox Laboratories has introduced a test for the COVID-19 strain of coronavirus and nine other respiratory viruses.
Direct HbA1c testing in whole blood
December 2019—The Randox RX series provides laboratories with the capabilities of onboard HbA1c testing in whole blood on three fully automated RX analyzers—RX Modena, RX Imola, and RX Daytona+ —to accommodate rapid and reliable measurement of HbA1c in different laboratory settings.
Randox launches assay for CVD risk assessment
November 2019—Randox introduced a research use only sPLA2-IIA assay for use on a range of clinical chemistry analyzers. The latex-enhanced immunoturbidimetric assay measures sPLA2-IIA mass levels.
Randox RX series gains NGSP certification
October 2019—Randox Laboratories announced that the NGSP has awarded it with a manufacturer certification for direct HbA1c testing on three of the company’s clinical chemistry analyzers, the RX Modena, RX Imola, and RX Daytona+.